2 min listen
Pharma and Biotech Daily: FDA Delays Decision on Donanemab, Biden Addresses Drug Prices, Brukinsa Approval, ALS Drug Uncertainty, and Industry Layoffs…
Pharma and Biotech Daily: FDA Delays Decision on Donanemab, Biden Addresses Drug Prices, Brukinsa Approval, ALS Drug Uncertainty, and Industry Layoffs…
ratings:
Length:
1 minute
Released:
Mar 11, 2024
Format:
Podcast episode
Description
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The FDA has delayed its decision on Eli Lilly's Alzheimer's drug, Donanemab, and will convene a committee to discuss the application. President Biden addressed drug prices in the State of the Union, calling for lower prescription drug prices. Additionally, Beigene's Brukinsa was approved for follicular lymphoma, and Amylyx's ALS drug faced uncertainty after a Phase III trial failure. Other news included BMS gaining FDA approval for Opdivo in first-line bladder cancer and Merck KGaA discontinuing a BTK inhibitor after a Phase III trial failure. The biopharma industry is experiencing layoffs, with companies like Sumitomo and Evonik cutting staff.
Released:
Mar 11, 2024
Format:
Podcast episode
Titles in the series (44)
Pharma and Biotech Daily: The Latest in FDA Approvals, Clinical Trial Results, Acquisitions, and Promising Vaccines by Pharma and BioTech Daily